1992
DOI: 10.3109/09546639209092765
|View full text |Cite
|
Sign up to set email alerts
|

Methylprednisolone aceponate (MPA)* — a new therapeutic for eczema: A pharmacological overview

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

1
21
0
2

Year Published

1994
1994
2017
2017

Publication Types

Select...
8
1

Relationship

1
8

Authors

Journals

citations
Cited by 18 publications
(24 citation statements)
references
References 3 publications
1
21
0
2
Order By: Relevance
“…Méthylprednisolone aceponate (MPA, Advantan'") is a new, nonhalogenated corticoid diester for the treatment of eczematous disor ders [ 1 ]. It is an effective new steroid.…”
Section: Introductionmentioning
confidence: 99%
“…Méthylprednisolone aceponate (MPA, Advantan'") is a new, nonhalogenated corticoid diester for the treatment of eczematous disor ders [ 1 ]. It is an effective new steroid.…”
Section: Introductionmentioning
confidence: 99%
“…The therapeutic action of MPA clearly exceeded that of hydrocortisone butyrate since it proved three times more effective. Investigations in humans, using thc UV erythema inhibition test, demonstrated an anti-inflammatory activity comparable to that of mometasone furoate [22].…”
Section: Discussionmentioning
confidence: 95%
“…Methylation at C-6 increases receptor binding -and therefore potency -while double esterification significantly increases lipophilicity, facilitating rapid and efficient penetration of the stratum corneum and increased bioavailability. 35,36 Unlike other potent Luger corticosteroids, MPA does not contain a halogen at C-9; this contributes to a high degree of dissociation between topical and systemic activity. 36 MPA is metabolized rapidly by esterases within the epidermis and dermis.…”
Section: Use Of Mpa In Admentioning
confidence: 98%